Highlights

  • Lumos Diagnostics Holdings (ASX:LDX) increased FY26 Revenue by 6% to US$13.19 million, while its net loss narrowed to US$4.95 million.
  • FebriDx revenue reached US$3.92 million in FY26, compared with US$0.42 million in the previous financial year.
  • By September 2026, FebriDx had reached 215 live US sites, while another 405 sites were undergoing evaluation.
  • At the time of writing this article, Lumos Diagnostics Holdings (ASX:LDX) was trading at AUD 0.105, up 5.00% during today’s trading session.

At the time of writing this article, Lumos Diagnostics Holdings (ASX:LDX) was trading at AUD 0.105, up 5.00% during today’s trading session. Lumos is an Australian-listed diagnostics company focused on developing, Manufacturing and commercialising point-of-care diagnostic technologies. Its operations include proprietary diagnostic products such as FebriDx as well as contract development and manufacturing services. During FY26 and the opening months of FY27, attention has centred on the US commercial rollout of FebriDx, expanded healthcare-site adoption and the company’s financial position following Capital raising activity.

Company Business

Lumos Diagnostics develops and manufactures rapid diagnostic tests intended for use close to the patient rather than through conventional central laboratory testing. Its activities include product development, manufacturing, regulatory support and commercialisation.

FebriDx is an important proprietary product within the portfolio. It is a rapid point-of-care test designed to assist clinicians in differentiating bacterial from non-bacterial acute respiratory infections. During 2026, the company continued expanding the product across the United States following receipt of FDA clearance with CLIA Waiver status.

Lumos also generates revenue from contract development and manufacturing services for external customers. In FY26, service revenue remained the larger revenue contributor, although product sales increased substantially as FebriDx commercial activity expanded. All FY26 revenue was generated in the United States.

Recent Development

In September 2026, Lumos reported further expansion of FebriDx across its priority US urgent-care accounts. The number of live FebriDx sites increased to 215 from 170 in July, while the number of sites evaluating the product rose to 405 from 350.

Two additional top-100 US urgent-care groups had progressed to deployment across more than 40 sites combined. Another two top-100 urgent-care groups were conducting clinical and economic validation across more than 45 sites combined.

Lumos is using a staged commercial model in which healthcare networks initially evaluate the product before progressing toward broader deployment. The company cited WellStreet Urgent Care as an example of this process, with FebriDx having expanded to 44 live locations following its initial pilot program. US sales are conducted through the company’s exclusive distribution partner, with Lumos recognising revenue when products are shipped to that distributor.

Earlier in 2026, Lumos also secured FDA CLIA waiver status for FebriDx, received related milestone payments and continued building distribution arrangements. These developments have shifted the operational focus toward utilisation, healthcare-network expansion and product supply.

Financial Performance and Sector Context

Lumos reported FY26 revenue of US$13.19 million, up 6.4% from US$12.40 million in FY25. Product revenue increased to US$4.28 million from US$1.82 million, while services revenue declined to US$8.91 million from US$10.58 million.

FebriDx contributed US$3.92 million of revenue during FY26, compared with US$0.42 million in FY25. Gross Profit was US$7.93 million, compared with US$7.81 million previously, while the gross Margin was 60.1% versus 63.0%.

The company reported a net loss after tax of US$4.95 million, narrowing from US$7.18 million in FY25. Adjusted EBITDA loss was US$2.78 million compared with US$3.42 million in the prior year.

Cash and cash equivalents stood at US$15.43 million at 30 June 2026, compared with US$1.96 million a year earlier. Net Assets increased to US$22.86 million from US$6.16 million. During FY26, Lumos also completed an A$20 million capital raising, providing additional funding for its US commercialisation activities.

The point-of-care diagnostics sector remains influenced by regulatory approvals, reimbursement arrangements, clinician adoption, healthcare-system purchasing processes and manufacturing capacity.

Risks to Consider

Lumos remains exposed to commercial execution risk as it expands FebriDx across US healthcare networks. Site evaluations may not necessarily convert into wider deployments, while product utilisation can vary between healthcare providers.

Other considerations include regulatory compliance, reimbursement conditions, manufacturing execution and customer concentration. In FY26, approximately 84.9% of external revenue was derived from four major customers, highlighting the relevance of customer concentration to financial performance.

What to Watch Next

Future developments include the pace at which FebriDx evaluation sites progress toward routine adoption, further deployment among priority US urgent-care groups and changes in product ordering volumes.

Investors may also monitor FY27 product revenue, manufacturing activity, contract development revenue and cash expenditure. Expansion beyond the existing 215 live US sites and progress across the 405 sites under evaluation will provide further information on the scale of FebriDx commercial adoption.

Key Insights

Lumos Diagnostics finished FY26 with higher revenue, increased FebriDx sales, a narrower statutory loss and a larger cash balance. Product revenue increased materially as FebriDx became a greater contributor to the business, while contract development and manufacturing services continued to account for the majority of total revenue.

The September 2026 update showed further expansion of FebriDx across US urgent-care networks, with 215 live locations and 405 sites under evaluation. Future monitoring will focus on conversion of evaluated sites into active users, product revenue, manufacturing requirements and the company’s financial expenditure as commercial activity develops.